Skip to main content
. 2022 Oct 18;119(43):e2205417119. doi: 10.1073/pnas.2205417119

Fig. 1.

Fig. 1.

dMP MOG subcutaneous treatment in advanced EAE reverses hind limb paralysis and shows lasting efficacy. (A) dMP schematic showing the MPs at the subcutaneous injection site. (B) Timeline of treatments and analysis. (C) EAE score curve and cumulative scores following subcutaneous dMP injection initiated at a score of 3 (complete hind limb paralysis) with a second injection 3 d later. Clinical scores from 0 to 4 are as follows: 1, limp tail; 2, weak hind limbs; 3, hind limb paralysis; and 4, complete hind limb paralysis and partial hind limb paralysis. Scoring took place every other day until the first mice showed scores, at which point scoring took place daily. The cumulative score took the sum of the scores following treatment and represents the disease severity over the course of the experiment. Score curves were representative of three experiments. n = 4 to 5/group in each experiment; *P < 0.05, comparing untreated and dMP MOG–treated mice. #P < 0.05, comparing dMP OVA and dMP MOG–treated mice. **P < 0.01.